Your session is about to expire
← Back to Search
Alkylating agents
Maveropepimut-S for Ovarian Cancer (AVALON Trial)
Phase 2
Waitlist Available
Research Sponsored by ImmunoVaccine Technologies, Inc. (IMV Inc.)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 23 months
Awards & highlights
AVALON Trial Summary
This trial is testing a new drug, maveropepimut-S, to see if it is effective and safe in treating ovarian cancer that has come back and is resistant to platinum-based drugs.
Eligible Conditions
- Platinum-resistant Epithelial Ovarian Cancer
AVALON Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ up to 23 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 23 months
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Secondary outcome measures
CA-125 Response
Disease Control Rate (DCR)
Duration of Response (DOR)
+6 moreOther outcome measures
Cell mediated immune response
Changes in Tumor Micro-environment (TME)
AVALON Trial Design
1Treatment groups
Experimental Treatment
Group I: MVP-S + CPAExperimental Treatment2 Interventions
All subjects will receive two doses of maveropepimut-S (q3w) followed by up to six doses (q8w) plus low-dose cyclophosphamide on a repeating cycle of one week on/one week off.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cyclophosphamide 50mg
2015
Completed Phase 2
~360
Find a Location
Who is running the clinical trial?
ImmunoVaccine Technologies, Inc. (IMV Inc.)Lead Sponsor
10 Previous Clinical Trials
566 Total Patients Enrolled
3 Trials studying Ovarian Cancer
250 Patients Enrolled for Ovarian Cancer
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You have another type of cancer, except for certain types of skin cancer or early-stage cancer that has been completely cured.You have recently had a condition called thyroiditis.You have experienced blockages in your intestines due to the disease in the past.You had a heart attack or stroke in the last 6 months.You have skin or blood vessel problems that are ongoing or have lasted for a long time.You are currently receiving chemotherapy, radiation therapy, or certain hormonal therapies for cancer.You have previously received vaccines or treatments that target the survivin protein, immune checkpoint inhibitors, IDO inhibitors, or cell-based therapies.You have a stomach or intestinal condition that may make it difficult for your body to absorb medication taken by mouth.You have a serious heart or lung condition that is not under control.You recently received a vaccine that contains live, weakened viruses.You have severe swelling in your legs or feet.
Research Study Groups:
This trial has the following groups:- Group 1: MVP-S + CPA
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
What is the highest quantity of participants for this clinical trial?
"Affirmative. Clinicaltrials.gov supports the assertion that this clinical trial is actively enrolling participants, for which it was first posted on July 1st 2022 and modified most recently on July 20th 2022. 73 individuals are required from 2 independent medical facilities to complete the study."
Answered by AI
How have trials of Maveropepimut-S demonstrated its safety for patients?
"There is some evidence of Maveropepimut-S's safety, giving it a score of 2 on our company's rating scale. No efficacy data has been collected for this Phase 2 trial yet."
Answered by AI
Are there any vacancies remaining in this clinical experiment?
"The clinical trial is still open for applicants based on the data hosted on clinicaltrials.gov. This research was initially posted on July 1st 2022 and most recently updated a few weeks later, in mid-July of that same year."
Answered by AI
Recent research and studies
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger